Cargando…
The Reasons for Discontinuation of Infliximab Treatment in Patients with Crohn's Disease: A Review of Practice at NHS Teaching Hospital
Introduction. There is little information on the reasons for discontinuing infliximab treatment in patients with Crohn's disease. The aim of this study was to document these reasons to determine if any were preventable which would allow patients to continue the therapy. Aims & Methods. A re...
Autores principales: | Krupa, Lukasz Z., Kennedy, Hugh J., Jamieson, Crawford P., Fisher, Nicola, Hart, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205613/ https://www.ncbi.nlm.nih.gov/pubmed/22111012 http://dx.doi.org/10.5402/2011/672017 |
Ejemplares similares
-
Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017) -
Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study
por: Hu, Huiqin, et al.
Publicado: (2017) -
Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease
por: Sakatani, Aki, et al.
Publicado: (2013) -
Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile
por: Medrano, Luz María, et al.
Publicado: (2015) -
Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)